MMS

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet

rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

Last week, the MMS team started moving more with our global 20-day walking, cycling, and swimming challenge, as part of ...
06/16/2026

Last week, the MMS team started moving more with our global 20-day walking, cycling, and swimming challenge, as part of our 20 Years of Impact celebrations.

Across teams and regions, colleagues are building healthier habits and supporting one another along the way. From daily walks to bike rides and swims, every mile (or minute) counts.

Great to see so many people getting involved and making the most of the challenge so far!

PSI 2026 starts today, and MMS is looking forward to connecting with teams in Belfast.From 15–17 June, our team will be ...
06/15/2026

PSI 2026 starts today, and MMS is looking forward to connecting with teams in Belfast.

From 15–17 June, our team will be joining the clinical research community at the ICC Belfast to share practical perspectives on biostatistics, clinical research, and data-driven decision-making.

If you’re attending, get in touch with our team to continue the conversation:
- Aiden Flynn, Senior Vice President of Strategic Statistical Services
- Sam Miller, Vice President of Strategic Statistical Services
- Amy Spencer, Senior Biostatistician
- Andrew Mills, Strategic Principal Statistician
- Frances Denny, Director of Business Operations
- Lesedi Ledwaba-Chapman, Software Engineer for KerusCloud Product Development
- Lucy Sutton, Vice President of Account Management

Book a meeting: https://hubs.li/Q04ln7wY0

MMS South Africa had the pleasure of attending the Engo Charity Concert, marking our fourth consecutive year supporting ...
06/12/2026

MMS South Africa had the pleasure of attending the Engo Charity Concert, marking our fourth consecutive year supporting this meaningful event.

Hosted in aid of Engo Children’s Homes, a non-profit that provides safe and supportive home environments to children in need, the evening was led by the children themselves, who delivered a genuinely moving performance that highlighted their talent and spirit. Following the concert, a charity auction featured artwork created by the children, helping raise additional funds for the homes.

The evening closed with a shared dinner, bringing together attendees in support of a cause that continues to make a real difference.
We’re proud to support Engo Children’s Homes and the important work they do.

Thank you to our MMS SA colleagues who attended:
- Diederik van Niekerk, Senior Director of Regional Business Operations and Development
- Toni-Jone De Jongh (Faihst), Associate Director of Regulatory and Medical Writing
- Liana Vermaak, Associate Manager of Human Resources
- Louise van Aswegen, Director of Biostatistics
- Japie Lowings, Senior Manager of Biostatistics
- Braam van Huyssteen, Systems Administrator

AI is already shaping how submission readiness is approached. In our latest blog, Ben Kaspar, Vice President of Regulato...
06/11/2026

AI is already shaping how submission readiness is approached. In our latest blog, Ben Kaspar, Vice President of Regulatory Strategy, explores how sponsors are moving away from broad AI adoption toward more targeted, workflow-specific use cases.

The organizations seeing the most impact aren’t moving fastest, they’re applying AI thoughtfully, with validation and oversight built in.

Read the full blog to see how AI is being used in practice: https://hubs.li/Q04l2N2j0

06/10/2026

We’re pleased to be sponsoring the Welcome Reception at PSI 2026 in Belfast.

Join us at The Northern Whig as the clinical research community comes together to connect, exchange ideas, and kick off the conference.

Hear from Frances Denny, Director of Business Operations, on what she’s looking forward to, from reconnecting with peers to key discussions on change management and the future of statistics.

Don’t miss the team’s presentations, exploring how statisticians can adapt to constant change, apply smarter simulation strategies, support oncology decision‑making, leverage AI in workflows, and build more effective FSP partnerships.

Click here to learn more: https://hubs.li/Q04ks3L20

Join us on June 24 at 11am EDT for our next webinar: The Shift Toward Parallel Submissions In Global Regulatory Strategy...
06/09/2026

Join us on June 24 at 11am EDT for our next webinar: The Shift Toward Parallel Submissions In Global Regulatory Strategy.

In this webinar, MMS regulatory strategists will share practical insights into planning and executing parallel global submissions, drawing on real-world experience across multiple agency interactions.

The session will focus on how these processes work in practice, including:
- Aligning strategy, timing, and content across regions
- Navigating operational challenges
- Applying practical, time-tested approaches to support more efficient submissions on compressed timelines

Ben Dudley, Chief Commercial Officer, MMS, will moderate the discussion with Amanda Beaster, Senior Director of Regulatory Strategy, MMS, Sharon Morton, Principal Regulatory Strategist, MMS, and Philippe Motté, CEO, Celestial Consulting & Coaching.

Register to join the discussion: https://hubs.li/Q04krHtc0

06/08/2026

We’ll be in Boston, MA, for the World Orphan Drug Congress!

From June 9 to 11, Amanda Beaster, Senior Director of Regulatory Strategy, and Amanda Sullivan Director of Business Development, will be representing MMS and joining conversations focused on advancing development strategies for rare diseases.

At MMS, we bring deep experience supporting orphan and rare disease programs, helping sponsors navigate complex regulatory requirements and accelerate development in small, high-need patient populations.

Hear from Amanda Beaster on what she's looking forward to discussing and what she finds valuable at events like these. Book a meeting today: https://hubs.li/Q04kt_pZ0

MMS is heading to BIO International Convention 2026 in San Diego.From June 22–25, we’ll be joining the global biotech co...
06/05/2026

MMS is heading to BIO International Convention 2026 in San Diego.

From June 22–25, we’ll be joining the global biotech community at one of the industry’s largest gatherings, bringing together leaders across clinical research, regulatory strategy, and drug development.

Many of the costliest development risks originate early, before a study even begins. Too often, misaligned endpoints, unclear regulatory strategy, or untested assumptions create downstream challenges that are expensive to fix. At MMS, we work with biotech and sponsor teams to address these risks upfront.

If you’re attending BIO, Ben Dudley, President and Chief Commercial Officer, Chris Schoonmaker, Chief Operating Officer, Aiden Flynn, Senior Vice President of Strategic Statistical Services, and Duane Robinson, Senior Director of Business Development, would welcome the opportunity to connect and share perspectives.

Book a meeting with our team: https://hubs.li/Q04jT2Pr0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category